A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

Internal tandem duplications in fms-like tyrosine kinase 3 (FLT3-ITDs) are common in acute myeloid leukemia (AML) and confer a poor prognosis. A sensitive and specific assay for the detection of minimal residual disease (MRD) in FLT3-ITD mutated AML could guide therapy decisions. Existing assays for...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood Adv
Auteurs principaux: Levis, Mark J., Perl, Alexander E., Altman, Jessica K., Gocke, Christopher D., Bahceci, Erkut, Hill, Jason, Liu, Chaofeng, Xie, Zhiyi, Carson, Andrew R., McClain, Valerie, Stenzel, Timothy T., Miller, Jeffrey E.
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2018
Sujets:
Myeloid Neoplasia
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5916006/
https://ncbi.nlm.nih.gov/pubmed/29643105
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018015925
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires